FDA Approves Drug for Adults with Rare Form of Bone Marrow Disorder

News
Article

FDA has approved Vonjo (pacritinib) capsules to treat adults with a rare form of bone marrow disorder.

FDA has granted accelerated approval for Vonjo (pacritinib) capsules to treat adults with myelofibrosis, a rare form of bone marrow disorder, along with low platelet levels.

Myelofibrosis disrupts blood cell production and causes extensive bone marrow scarring, which can lead to severe anemia and a reduced number of platelets. This can increase the risk of bleeding and cause the spleen to enlarge. Myelofibrosis can be a primary or secondary disease, occurring on its own or developing due to another bone marrow disorder, respectively.

The effectiveness of pactirinib was based on the number of patients who had a 35% or greater spleen volume reduction from the start of the study to week 24. Twenty-nine percent of patients in the pactirinib treatment group experienced a spleen volume reduction of 35% or more, compared to the 3% in the standard treatment group.

Accelerated approval was granted on the condition that pactirinib must go through another study that confirms that spleen volume reduction leads to clinical benefits for the patients, such as improvements in function or feeling.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes